Evidence map›Paper›PMID 38109088›Full record

ArticleJAMA neurology2024

Direct to Consumer Biomarker Testing for Alzheimer Disease-Are We Ready for the Insurance Consequences?

Jalayne J Arias, Margaret Manchester, James Lah

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAMA neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Global multi-specialty clinician perspectives on the implementation of Alzheimer's disease blood biomarkers.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jalayne J AriasDepartment of Health Policy and Behavioral Sciences, School of Public Health, Georgia State University, Atlanta.
Margaret ManchesterDepartment of Health Policy and Behavioral Sciences, School of Public Health, Georgia State University, Atlanta.
James LahDepartment of Neurology, Emory University, Atlanta, Georgia.

Funding

Employment and Insurance Discrimination Based on Biomarkers for Alzheimer's diseaseK01AG057796 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ARIAS, JALAYNE J · 2018 to 2022
$652k
NIA NIH HHS K01 AG057796
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Alzheimer DiseaseDirect-To-Consumer Screening and TestingInsuranceBiomarkersGenetic TestingHumansBiomarkers

Identifiers

PMID38109088
PMCPMC12795088

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.